| 1 |
34825396 | Neuropathology of a patient with Alzheimer disease treated with low doses of verubecestat. | 2022 Apr |
1 |
| 2 |
33252075 | Retinal Optical Coherence Tomography Metrics Are Unchanged in Verubecestat Alzheimer's Disease Clinical Trial but Correlate with Baseline Regional Brain Atrophy. | 2021 |
2 |
| 3 |
31347728 | BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease. | 2020 Jan |
1 |
| 4 |
33253354 | BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain. | 2020 Dec 1 |
1 |
| 5 |
30347431 | Pharmacokinetics and Pharmacodynamics of the BACE1 Inhibitor Verubecestat (MK-8931) in Healthy Japanese Adults: A Randomized, Placebo-Controlled Study. | 2019 May |
2 |
| 6 |
31215755 | Safety, Tolerability, and Pharmacokinetics of the β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitor Verubecestat (MK-8931) in Healthy Elderly Male and Female Subjects. | 2019 Sep |
1 |
| 7 |
31423903 | Lessons that can be learnt from the failure of verubecestat in Alzheimer's disease. | 2019 Dec |
2 |
| 8 |
29481097 | A Next Generation Synthesis of BACE1 Inhibitor Verubecestat (MK-8931). | 2018 Mar 16 |
1 |
| 9 |
27807285 | The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients. | 2016 Nov 2 |
2 |
| 10 |
27933948 | Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease. | 2016 Dec 8 |
2 |
| 11 |
27934506 | Synthesis of Verubecestat, a BACE1 Inhibitor for the Treatment of Alzheimer's Disease. | 2016 Nov 18 |
1 |